Pavlina Konstantinidou
Overview
Explore the profile of Pavlina Konstantinidou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
166
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Verrou E, Tsirou K, Karampatzakis N, Triantafyllou T, Sevastoudi A, Grigoriadou G, et al.
Leuk Res Rep
. 2021 Aug;
16:100261.
PMID: 34401318
Herein we present a rare case of two brothers diagnosed with CML four years apart. Importantly, our case of CML occurrence among siblings is the fifth one reported and the...
2.
Hadjiaggelidou C, Douganiotis G, Tsirou K, Verrou E, Triantafyllou T, Keramidioti K, et al.
Leuk Lymphoma
. 2021 Jun;
62(12):3054-3056.
PMID: 34151719
No abstract available.
3.
Vassilakopoulos T, Michail M, Papageorgiou S, Kourti G, Angelopoulou M, Panitsas F, et al.
Oncologist
. 2021 Apr;
26(7):597-609.
PMID: 33870594
Background: R-CHOP can cure approximately 75% of patients with primary mediastinal large B-cell lymphoma (PMLBCL), but prognostic factors have not been sufficiently evaluated yet. R-da- EPOCH is potentially more effective...
4.
Dimou M, Papageorgiou S, Stavroyianni N, Katodritou E, Tsirogianni M, Kalpadakis C, et al.
Hematol Oncol
. 2021 Feb;
39(3):336-348.
PMID: 33583077
Transplant-ineligible relapsed/refractory (rr) diffuse large B-cell lymphoma (DLBCL) patients represent an unmet medical need. Polatuzumab vedotin (Pola), an anti-CD79b antibody-drug-conjugate (ADG), with bendamustine- rituximab(BR) has recently gained approval for these...
5.
Vassilakopoulos T, Papageorgiou S, Angelopoulou M, Chatziioannou S, Prassopoulos V, Karakatsanis S, et al.
Ann Hematol
. 2021 Feb;
100(9):2279-2292.
PMID: 33523289
End-of-treatment (EoT) PET/CT is used as a guide to omit radiotherapy (RT) patients with primary mediastinal large B-cell lymphoma (PMBCL). We present the mature and extended results of a retrospective...
6.
Hadjiaggelidou C, Vadikolia C, Verrou E, Yiannaki E, Triantafyllou T, Palaska V, et al.
Hemasphere
. 2020 Dec;
5(1):e506.
PMID: 33324952
No abstract available.
7.
Katodritou E, Kastritis E, Gatt M, Cohen Y, Avivi I, Pouli A, et al.
Am J Hematol
. 2020 Feb;
95(5):465-471.
PMID: 32048329
We investigated incidence, characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) treated mainly with novel therapies. Based on definition (BMPCs <20% and lytic lesions/plasmacytomas, without anemia, renal insufficiency...
8.
Hadjiaggelidou C, Mandala E, Terpos E, Yiannaki E, Markala D, Triantafyllou T, et al.
Ann Hematol
. 2019 Mar;
98(6):1457-1466.
PMID: 30895351
The exact role of regulatory T cells (Tregs) in multiple myeloma (MM) has not been yet determined. Data regarding alterations of Tregs during therapy with novel agents (NA), i.e., bortezomib...
9.
Terpos E, Katodritou E, Symeonidis A, Zagouri F, Gerofotis A, Christopoulou G, et al.
Int J Cancer
. 2019 Jan;
145(2):559-568.
PMID: 30650184
There is limited data regarding the efficacy and safety of lenalidomide, adriamycin and dexamethasone (RAD) combination on newly diagnosed multiple myeloma (NDMM) patients. There is also scarce information about the...
10.
Katodritou E, Terpos E, Delimpasi S, Kotsopoulou M, Michalis E, Vadikolia C, et al.
Blood Cancer J
. 2018 Mar;
8(3):31.
PMID: 29523783
We have studied the efficacy and the prognostic impact of novel agents in 50 primary plasma cell leukemia (pPCL) patients registered in our database. Eighty percent of patients were treated...